
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Apexian Pharmaceuticals | APX3330 | advanced solid tumors | Phase I trials initiated |
Bavarian Nordic | BN-Brachyury | cancer metastasis | Phase I trials initiated enrolling 10 subjects |
Protalex | PRTX-100 (PRTX-100-203 Study) | persistent/chronic Immune Thrombocytopenia | Phase Ib trials initiated enrolling 30 subjects in Europe |
IntelGenx | Montelukast VersaFilm | Alzheimer’s disease | Phase IIa trials initiated |
Biomarck Pharmaceutical | BIO-11006 | non-small cell lung cancer | Phase II trials initiated in India |
Melinta Therapeutics | radezolid | bacterial vaginosis | Phase II trials initiated |
TrovaGene | PCM-075 + Zytiga | metastatic castration-resistant prostate cancer | Phase II trials initiated enrolling 25 subjects |
Evofem Biosciences | Amphora | prevention of urogenital chlamydia and gonorrhea in women | Phase IIb/III trials initiated enrolling 850 subjects in the U.S. |
GC Pharma | GC1102 | hepatitis B virus infection following liver transplantation | Phase II/III trials planned |
Swedish Orphan Biovitrum | SOBI003 | mucopolysaccharidosis type IIIA | Fast Track designation granted by the FDA |
Astellas Pharma | gilteritinib | acute myeloid leukemia | Orphan Drug designation granted by the EC |
BERG | BPM31510 | pancreatic cancer | Orphan Drug designation granted by the FDA |
Enzychem Lifesciences | EC-18 | acute radiation syndrome | Orphan Drug designation granted by the FDA |
Nohla Therapeutics | NLA101 | hematopoietic stem cell transplantation | Orphan Drug designation granted by the EC |
Omeros | OMS721 | primary Immunoglobulin A nephropathy | Orphan Drug designation granted by the EMA |
Orphazyme | arimoclomol | Niemann-Pick disease Type C | Rare Pediatric Disease designation granted by the FDA |
Genmab | daratumumab (Darzalex) + bortezomib, melphalan and prednisone | newly diagnosed multiple myeloma | Priority Review granted by the FDA |
Baxter International | Bivalirudin | anticoagulant in patients undergoing percutaneous coronary intervention | FDA approved |
Bristol-Myers Squibb | Yervoy (ipilimumab) | advanced (unresectable or metastatic) melanoma in pediatric patients 12 years of age and older | EC expanded indication approved |
Takeda Pharmaceutical | Adcetris (brentuximab vedotin) | CD30-positive cutaneous T-cell lymphoma | EC extended current conditional marketing authorization |
Upcoming Events
-
14Apr